In Cathie Wood’s Ark Genomic Revolution ETF (NYSEMKT: ARKG), as of July 10, the three top holdings are Tempus AI, 10x Genomics, and Twist Bioscience.
But digging past the top 10 holdings, there’s a $1.8 billion biotech company with a growing drug pipeline that’s also landed big-name healthcare partnerships
That company is Recursion Pharmaceuticals (NASDAQ: RXRX), and the Ark Genomic Revolution ETF currently owns over $50 million worth of its stock. Utilizing AI in drug discovery As more companies tap into the power of artificial intelligence (AI) to accelerate drug discovery and uncover novel solutions, Recursion stands out for the massive amount of data it can generate, as well as for its partnerships. Each week, it uses robotics and computer vision to capture millions of cell experiments, potentially helping to speed up drug development.
It currently has seven drugs in various clinical stages in its pipeline, and its candidate REC-4881, designed to treat a rare genetic condition that can lead to cancer, is one of the drugs that’s furthest along in trials. REC-4881 has shown positive proof-of-concept data, with additional phase 1b/2 data expected in the first half of 2027. For its therapeutic partnerships, Recursion is working with some of the largest companies in Europe, including Bayer and Roche Holding.